Infectious Diseases (all articles)
RCT: CPAP improved outcomes in patients with acute hypoxemic respiratory failure due to COVID-19, but high-flow nasal oxygen was not better than conventional oxygen therapy.
25 Jan, 2022 | 09:50h | UTCEditorial: Defining Optimal Respiratory Support for Patients With COVID-19 – JAMA
Commentary on Twitter
RCT of patients with acute hypoxemic respiratory failure due to #COVID19 found an initial strategy of CPAP, compared with conventional oxygen therapy, significantly reduced the composite outcome of tracheal intubation or mortality within 30 days. https://t.co/fznFigiFmu pic.twitter.com/b7mHssbfkp
— JAMA (@JAMA_current) January 24, 2022
ACP living, rapid review: risk for reinfection after SARS-CoV-2.
25 Jan, 2022 | 09:47h | UTC
Commentary on Twitter
Risk for Reinfection After #SARSCoV2: previous infection reduced risk for reinfection by 87% (95% CI, 84% to 90%). Protection remained above 80% for at least 7 months, but no study followed patients after the emergence of the Delta or #Omicron variant. https://t.co/eruEf1w8Vo
— Prof. Nick Talley (@Prof_NickTalley) January 25, 2022
New CPR guidance addresses more contagious COVID-19 variants amidst evolving pandemic.
25 Jan, 2022 | 09:48h | UTCNews release: New CPR guidance addresses more contagious COVID-19 variants amidst evolving pandemic – American Heart Association
WHO drops opposition to boosters – recommends third Pfizer jab for adults & two vaccines for children ages 5 & up.
25 Jan, 2022 | 09:45h | UTCRelated:
WHO updated roadmap for prioritizing uses of COVID-19 vaccines.
WHO advisers weigh in on COVID-19 boosters, Pfizer vaccine in younger kids.
A case-control study showed an increased risk of myocarditis after COVID-19 vaccination with a messenger RNA vaccine compared to an inactivated virus vaccine.
25 Jan, 2022 | 09:43h | UTCNews release: BNT162b2 COVID-19 vaccine associated with increased risk of carditis – American College of Physicians
Related:
[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.
Heart-inflammation risk from Pfizer COVID vaccine is very low.
Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa.
25 Jan, 2022 | 09:41h | UTCCommentary: Omicron severity: milder but not mild – The Lancet
Commentary on Twitter
Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in S. Africa, Lancet. Individuals with Omicron vs previous infections 80% lower odds of being admitted to hospital, 70% lower odds of severe disease than Deltahttps://t.co/528NWfKrDN
— Monica Gandhi MD, MPH (@MonicaGandhi9) January 23, 2022
COVID-19: endemic doesn’t mean harmless.
25 Jan, 2022 | 09:36h | UTCCOVID-19: endemic doesn’t mean harmless – Nature
[Preprint] Cohort study: Reduced risk of hospitalization associated with infection with SARS-CoV-2 Omicron relative to Delta.
25 Jan, 2022 | 09:40h | UTCCommentaries:
Danish report: lower risk of hospitalisation with Omicron – Copenhagen Post
Commentary on Twitter
New Danish population-based cohort study confirms lower (36%, 95%CI 44%-25%) risk of hospitalization with Omicron compared with Delta.
The risk also seems to be reduced irrespective of vaccination status.Pre-print can be found here: https://t.co/LfRrw1H3CY pic.twitter.com/Ql3zPyZyRE
— Anders Husby (@a_husby) January 20, 2022
We will be living with COVID for foreseeable future; but we can end acute phase of pandemic this year — WHO Director General.
25 Jan, 2022 | 09:34h | UTC
[Preprint] Omicron SARS-CoV-2 variant is associated with reduced risk of hospitalization and length of stay compared with Delta.
25 Jan, 2022 | 09:37h | UTC
Commentary on Twitter
In Portugal, Omicron hospitalizations were 75% reduced compared with Delta, risk adjusted. Vaccination reduced hospitalizations 84%, w/a booster 93%https://t.co/MvkfuF3mzx pic.twitter.com/zyk2INWNis
— Eric Topol (@EricTopol) January 23, 2022
RCT: Single-dose 1000 mg ertapenem is non-inferior to single-dose 500 mg ceftriaxone for the treatment of gonorrhea.
25 Jan, 2022 | 09:20h | UTCEfficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial – The Lancet Infectious Diseases (link to abstract – $ for full-text)
Commentary on Twitter (thread – click for more)
New from @TheLancetInfDis Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial by @henryjdevries and colleagues https://t.co/K2fw5ORNlm pic.twitter.com/d8wz1Vc41Q
— The Lancet HIV (@TheLancetHIV) January 24, 2022
Cohort study: In patients with a prosthetic joint, prophylactic antibiotics are probably not needed for invasive dental procedures.
25 Jan, 2022 | 09:11h | UTCCommentary: Prophylactic Antibiotics Not Needed Before Invasive Dental Procedures – HealthDay
Commentary on Twitter
Case-crossover study analyzing the incidence of invasive dental procedures (IDP) over the 15-months before 9,427 late prosthetic joint infection hospital admissions (LPJI) and found no evidence of a temporal association b/w IDP and LPJI. https://t.co/hcpwpN0B4H
— JAMA Network Open (@JAMANetworkOpen) January 19, 2022
European CDC on Omicron: “among Omicron cases reported to TESSy, 1.14% were hospitalised, 0.16% required ICU admission/respiratory support, and 0.06% died”.
24 Jan, 2022 | 08:54h | UTC
Case-control study: 3 doses of mRNA vaccines were associated with reduced infections with SARS-CoV-2 Omicron and Delta variants compared to no vaccination or 2 doses.
24 Jan, 2022 | 08:56h | UTCCommentaries: New data show booster doses protect against Omicron – CIDRAP
Related CDC Studies:
Commentary on Twitter
Study suggests receipt of 3 doses of mRNA #COVID19 vaccine, vs 2 doses or being unvaccinated, was associated with protection against both the Omicron and Delta variants; higher odds ratios for Omicron suggest less protection for Omicron than for Delta. https://t.co/kOZh0fq5TL
— JAMA (@JAMA_current) January 21, 2022
WHO updated roadmap for prioritizing uses of COVID-19 vaccines.
24 Jan, 2022 | 08:49h | UTCWHO SAGE Roadmap for prioritizing uses of COVID-19 vaccines – World Health Organization
Commentary: WHO: COVID boosters should start with most vulnerable – Associated Press
Commentary on Twitter (thread – click for more)
UPDATED: The Strategic Advisory Group of Experts (SAGE) have revised the Roadmap for Prioritising Uses of #COVID19 vaccines.
👉 https://t.co/FJFlMpBSSK pic.twitter.com/4SNH7ZpSwz
— World Health Organization (WHO) (@WHO) January 21, 2022
WHO advisers weigh in on COVID-19 boosters, Pfizer vaccine in younger kids.
24 Jan, 2022 | 08:35h | UTCWHO advisers weigh in on COVID-19 boosters, Pfizer vaccine in younger kids – CIDRAP
Updated Guideline: Recommended drugs and biologics in adult patients with COVID-19.
24 Jan, 2022 | 08:52h | UTC
Commentary on Twitter (thread – click for more)
https://twitter.com/ASPphysician/status/1484874519252721664
WHO Technical Brief: Enhancing response to Omicron SARS-CoV-2 variant.
24 Jan, 2022 | 08:36h | UTCEnhancing response to Omicron SARS-CoV-2 variant – World Health Organization
A guide to immunotherapy for COVID-19.
24 Jan, 2022 | 08:29h | UTCA guide to immunotherapy for COVID-19 – Nature Medicine
A blood atlas of COVID-19 defines hallmarks of disease severity and specificity.
24 Jan, 2022 | 08:28h | UTCA blood atlas of COVID-19 defines hallmarks of disease severity and specificity – Cell
Commentary on Twitter:
A simple😉one-page summary of everything you need to know about Covid hallmarks of severity in the blood, how it differs from flu, sepsis, and much morehttps://t.co/s81Qb2SXmu @CellCellPress @KnightGenetics
(actually quite a rich resource @UniofOxford) pic.twitter.com/bk0AxwLItn— Eric Topol (@EricTopol) January 22, 2022
Flying in the COVID-19 era: Science-based risk assessments and mitigation strategies on the ground and in the air.
24 Jan, 2022 | 08:32h | UTCFlying in the COVID-19 Era: Science-based Risk Assessments and Mitigation Strategies on the Ground and in the Air – National Academies of Sciences, Engineering, and Medicine (free registration required)
SARS-CoV-2 breakthrough infections elicit potent, broad and durable neutralizing antibody responses.
24 Jan, 2022 | 08:26h | UTCNews Release: Breakthrough infections spur strong antibody responses – University of Washington School of Medicine
AHA Statement: Oral penicillin, not injectable, advised for people with high-risk rheumatic heart disease.
24 Jan, 2022 | 08:21h | UTCNews Release: Oral penicillin, not injectable, advised for people with high-risk rheumatic heart disease – American Heart Association
The WSES/SICG/ACOI/SICUT/AcEMC/SIFIPAC guidelines for diagnosis and treatment of acute left colonic diverticulitis in the elderly.
24 Jan, 2022 | 08:24h | UTCRelated:
ACP Guideline: Diagnosis and management of acute left-sided colonic diverticulitis.
Review: Changing paradigms in the management of acute uncomplicated diverticulitis.
Review: Elective surgical management of diverticulitis
State of the Art Review | Management of colonic diverticulitis
Drains, germs, or steel: Multidisciplinary management of acute colonic diverticulitis
Systematic review: Management of colonic diverticulitis
WSES Guidelines for the Management of Acute Colonic Diverticulitis
ASCRS Guidelines for the Treatment of Left-Sided Colonic Diverticulitis
Opinion: COVID-19 will continue but the end of the pandemic is near.
21 Jan, 2022 | 10:16h | UTCCOVID-19 will continue but the end of the pandemic is near – The Lancet
Commentary on Twitter
.@IHME_UW's Chris Murray predicting the end of the pandemic is nigh
"More than 50% of the world will have been infected with omicron …[by] the end of March, 2022"
"After the omicron wave, COVID-19 will return but the pandemic will not."https://t.co/9NSw8lZuUe @TheLancet— Eric Topol (@EricTopol) January 20, 2022